Clinical trial · Interventional
Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer
Phase II Study to Determine the Efficacy of OSI-211 (Liposomal Lurtotecan) Given on Days 1, 2 & 3 Every 3 Weeks in Patients With Recurrent Small Cell Lung Cancer
NCT00046787CI-TRIAL-00005662completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether OSI-211 (Liposomal Lurtotecan) is an effective and safe treatment for patients with recurrent small cell lung cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Small Cell | Small Cell Neuroendocrine Carcinoma | ALIAS | 0.90 |
| SCLC | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| OSI-211 (Liposomal Lurtotecan) | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed recurrent small cell lung cancer. * One prior treatment of chemotherapy. * At least three weeks since last chemotherapy treatment and recovery from any related side effects. * At least three weeks since last chest radiotherapy and at least 10 days since head irradiation and recovery from acute side effects. * At least one target tumor less than or equal to 20 mm (or less than or equal to 10 mm on spiral CT-scan). * If a patient has had previous documented Central Nervous System (CNS) involvement, only controlled disease is acceptable. Exclusion Criteria: * Superior vena cava syndrome.
References
Publications (0)
Data not yet available
No reference posted for this study.